CAR-T输注后绝对淋巴细胞计数增殖动力学影响缓解与复发
该研究纳入166例接受CD19 CAR-T治疗的B-ALL患者,分析输注后淋巴细胞计数及形态变化与疗效的关系。结果显示持续缓解者峰值绝对淋巴细胞计数及总体扩增高于无应答者,BCA早期丢失及CD19+ MRD/复发者总体淋巴细胞扩增较低。结论认为淋巴细胞计数及分类可用于评估CAR-T扩增。
要点
- CAR-T输注后第二周绝对淋巴细胞计数快速扩增,伴非典型淋巴细胞出现。
- 持续缓解者峰值绝对淋巴细胞计数及总体扩增高于无应答者。
- BCA早期丢失及CD19+ MRD/复发者总体淋巴细胞扩增较低。
核心结论
- 淋巴细胞计数及分类可结合BCA和CRS用于评估CAR-T输注后扩增。
研究设计与样本
- 回顾性分析166例接受CD19 CAR-T治疗的B-ALL患者的常见血液学实验室参数。
主要发现
- 86%患者循环原始细胞消失,中位时间6天。
- 第二周绝对淋巴细胞计数快速扩增,伴非典型淋巴细胞出现,随后收缩期非典型淋巴细胞减少。
- 持续缓解者峰值绝对淋巴细胞计数及总体扩增高于无应答者。
- BCA早期丢失及最终CD19+ MRD/复发者总体淋巴细胞扩增低于对照。
- CAR-T后脑脊液可见多形性淋巴细胞增多。
临床怎么用
- 可利用淋巴细胞计数及分类辅助评估CAR-T输注后扩增,结合BCA和CRS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CAR) T cells show characteristic proliferation kinetics after infusion that correlate with response. Clearance of circulating disease, B-cell aplasia (BCA), and cytokine release syndrome (CRS) are used to observe CAR T-cell function, given the lack of commercial CAR T-cell measurement assays. We investigated the utility of common hematology laboratory parameters in 166 patients with B-cell acute lymphoblastic leukemia (B-ALL) who were treated with CAR T-cell therapy targeting CD19. CAR T-cell infusion was followed by disappearance of circulating blasts in 86% of patients at a median of 6 days. After a lag phase, there was a rapid expansion in absolute lymphocyte count (ALC) in the second week that coincided with the appearance of atypical lymphocytes. The expansion phase was followed by a contraction phase with a concomitant decrease in atypical lymphocytes. In vitro CAR T-cell studies showed similar kinetics and morphological changes. Peak ALC and overall expansion was greater in sustained responders compared with that in nonresponders. Patients with early loss of BCA and those with eventual CD19+ minimal residual disease/relapse showed lower overall lymphocyte expansion compared with the controls. Pleomorphic lymphocytosis was noted in the cerebrospinal fluid at post-CAR time points. We conclude that lymphocyte counts and differential can also be used to evaluate CAR T-cell expansion after infusion, along with BCA and CRS. This is the first report to characterize the morphology of CAR T cells and determine the utility of lymphocyte kinetics.
引用
- Faude S, Wei J, Muralidharan K, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 2021. PMID: 33881465. doi:10.1182/bloodadvances.2020004038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。